Barry D. Quart - 29 Nov 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
29 Nov 2022
Transactions value $
-$319,723
Form type
4
Filing time
01 Dec 2022, 15:16:00 UTC
Previous filing
17 Oct 2022
Next filing
17 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $34.9K +22K $1.59* 22K 29 Nov 2022 Direct
transaction KNSA Class A Common Share Sale -$355K -22K -100% $16.15 0 29 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -22K -100% $0.00* 0 29 Nov 2022 Class A Common Share 22K $1.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.09 to $16.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Class A Common Shares sold at each price.
F2 The option is fully vested and exercisable.